Alvin John Liu

Mr. Alvin John Liu

Northeast Ohio Medical University, Ravenna, Ohio, USA
+1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
VSVikash Singh
Vikash Singh
ASAmandeep Singh
Amandeep Singh
Alvin John LiuAlvin John Liu
Alvin John Liu
SFSerge Fuchs
Serge Fuchs
Arun SharmaArun Sharma
Arun Sharma
Vladimir SpiegelmanVladimir Spiegelman
Vladimir Spiegelman
RNA-binding proteins (RBPs) play critical roles in regulating post-transcriptional gene expression, managing processes such as mRNA splicing, stability, and translation. In normal intestine, RBPs maintain the tissue homeostasis, but when dysregulated, they can drive colorectal cancer (CRC) development and progression. Understanding the molecular mechanisms behind CRC is vital for developing novel therapeutic strategies, and RBPs are emerging as key players in this area. This review highlights the roles of several RBPs, including LIN28, IGF2BP1–3, Musashi, HuR, and CELF1, in CRC. These RBPs regulate key oncogenes and tumor suppressor genes by influencing mRNA stability and translation. While targeting RBPs poses challenges due to their complex interactions with mRNAs, recent advances in drug discovery have identified small molecule inhibitors that disrupt these interactions. These inhibitors, which target LIN28, IGF2BPs, Musashi, CELF1, and HuR, have shown promising results in preclinical studies. Their ability to modulate RBP activity presents a new therapeutic avenue for treating CRC. In conclusion, RBPs offer significant potential as therapeutic targets in CRC. Although technical challenges remain, ongoing research into the molecular mechanisms of RBPs and the development of selective, potent, and bioavailable inhibitors should lead to more effective treatments and improved outcomes in CRC.

3 June 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
Dechang ChenDechang Chen
Dechang Chen
Alvin John LiuAlvin John Liu
Alvin John Liu
LSLi Sheng
Li Sheng
ZLZhenqiu Liu
Zhenqiu Liu
IEIrina Elcheva
Irina Elcheva
Background: While adult and pediatric acute myeloid leukemia (AML) exhibit genetic distinctions, investigating their common gene expression program is critical for understanding the fundamental biological mechanisms that drive diverse cellular responses. However, existing gene signatures, predominantly tailored for overall survival (OS), may not adequately forecast event-free survival (EFS). EFS represents the time patients survive without disease recurrence, progression, or further treatment, a crucial metric for evaluating drug efficacy and assessing the clinical benefits of treatment. Methods: We performed an integrated analysis of adult TCGA and pediatric TARGET expression datasets to pinpoint genes and pathways associated with EFS in both adult and pediatric AML. Additionally, we constructed a predictive model using one dataset and validated it on the other to unveil a novel gene signature. Results: A five-gene signature comprising F2RL3, IL2RA, MYH15, SIX3, and SOBP was identified for EFS for both adult and pediatric AML. The test Area Under the ROC Curves (AUCs) for the 2-year and 5-year cutoffs of adult TCGA data were 0.851 (95% CI (Confidence Interval): 0.778–0.923) and 0.848 (95% CI: 0.729–0.968), respectively. Similarly, the test AUCs for the 2-year and 5-year cutoffs of Pediatric TARGET data were 0.725 (95% CI: 0.640–0.811) and 0.695 (95% CI: 0.59–0.80), respectively. When patients were stratified into three equal-sized prognostic subtypes based on the five-gene test risk scores, the P-values of tertile partitions for TARGET and TCGA data were 2.32e−6 and 5.12e−14, respectively, indicating superior performance compared to cytogenetic risk stratification within the same data (TARGET: P = 0.0019; TCGA: P = 0.0086). Despite being identified for EFS, the five-gene signature successfully stratified patients into distinct OS groups across two additional independent datasets. Conclusions: This five-gene signature demonstrates robust performance in both EFS and OS risk prediction and might be clinically significant.